Loading…
← CockpitCompetitor Analysis › MANKIND.NS Mankind PharmaOpen in the cockpit ↗

Mankind PharmaMANKIND.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Indian branded-generics and consumer-healthcare maker known for OTC brands like Manforce and Prega News, plus prescription drugs.

≈ India's OTC-and-generics hybrid, part Cipla part J&J consumerMomentum strong 77
Mkt cap
$11.6B
US dollars, full cap
Free float
27%
of shares outstanding
$/day
$20.0M
20-day average traded
Fwd P/E
44.4×
forward earnings
ROIC−WACC
+0.5 pp
WACC 10.8%
Hurdle
+10 pp
Req g minus delivered
Next earnings
77 days
3 Feb 2027
Close · INR₹2,625
1D+0.6%
1W-1.3%
1M+16.5%
3M+10.3%
6M+5.3%
YTD+19.5%
1Y+15.6%
ATR %2.5%
Beta0.55
52w lowhigh3.0% off high

What Mankind Pharma does

Indian branded-generics and consumer-healthcare maker known for OTC brands like Manforce and Prega News, plus prescription drugs.

Sells prescription drugs through a very large force of sales representatives who visit doctors and chemists, and consumer brands such as Manforce condoms and Prega News pregnancy kits through pharmacies and shops. Most sales are in India. The 2024 purchase of Bharat Serums and Vaccines added women's health and critical-care products. The Juneja family are the promoters.

In one line: India's OTC-and-generics hybrid, part Cipla part J&J consumer.

Products and services

  • Prescription formulations
  • Consumer healthcare (Manforce, Prega News, Unwanted-72)
  • Anti-infectives
  • Chronic therapies (cardiac, diabetes)

Customers

  • Retail pharmacies (India)
  • Hospitals
  • Consumers (OTC)

Where it sits in the supply chain

  • Pharmaceuticals
  • Branded generics
  • Consumer healthcare / OTC

What could go right

  • India's growing branded generics/OTC market
  • Chronic disease therapy expansion

What could go wrong

  • Price controls (NPPA) on essential drugs
  • Intense domestic competition

Moat: narrow (brand, distribution). Strong consumer brand recall and one of India's largest pharma field forces.

Headquarters: New Delhi, India · Founded: 1995 · Employees: 27,000

Named competitors

Mankind Pharma at a glance

Size Mankind Pharma (MANKIND.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $11.6B, the 106th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹2,625 on 18 Nov 2026.

Performance Over six months the shares gained 5.3%, against +7.6% for the median peer and +3.8% for the India market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue grew 13.3% over the last twelve months (peer median +14.5%); the operating margin is 20.6% (peer median 20.1%).

Valuation It trades at 44.4× forward earnings against a peer median of 30.9× (5th most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 29% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is +10 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.5 points above its cost of capital (10.8% WACC).

Next results Next results expected around 3 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 108MANKIND.NS 102
Six months, rebased to 100: Mankind Pharma against the median of its 20 peers (local-currency closes).

Mankind Pharma financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹154B₹143B₹122B₹103B₹87.4B
Revenue growth—+17%+19%+17%—
Gross profit₹67.9B₹56.4B₹50.4B₹41.2B₹33.9B
EBITDA₹40.8B₹36.6B₹31.0B₹25.6B₹19.4B
Net income₹22.4B₹19.1B₹19.9B₹19.1B₹12.8B
Free cash flown/a₹18.9B₹19.1B₹18.4B₹9.96B
Capital expendituren/a₹7.37B₹5.31B₹3.89B₹8.32B
Total debt₹54.2B₹63.1B₹85.1B₹2.07B₹1.70B

Quarterly statements and history in the cockpit →

Mankind Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%-10%0%+10%+20%600436RECRGEN1177DRREDDYZYDUSLIFE6990TGTXLAURUSLABS300759SYREMDGLHLUN-AIPN6885060005386446ORNAVPRAXJAZZMANKIND.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Mankind Pharma is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×500×1,000×600436RECRGEN1177DRREDDY6990TGTXLAURUSLABSMDGL6446ORNAVMANKIND.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Mankind Pharma is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%+400%0%200%400%600436RECRGEN1177TGTX6446MANKIND.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Mankind Pharma is the large dot.

Mankind Pharma competitors and peer comparison

Head to head with its named competitors (MANKIND.NS vs SUNPHARMA.NS vs CIPLA.NS vs ZYDUSLIFE.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Mankind Pharma MANKIND.NS$11.6B+5%+13%21%44.4×28.6%
Sun Pharmaceutical Industries SUNPHARMA.NS$48.0B-1%+12%23%36.0×28.7%
Cipla CIPLA.NS$12.2B+1%-1%13%29.1×28.4%
Zydus Lifesciences ZYDUSLIFE.NS$12.8B+18%+24%17%30.0×n/a
Lupin LUPIN.NS$9.67B-14%+24%24%21.0×8.8%
Torrent Pharmaceuticals TORNTPHARM.NS$18.8B+3%+42%22%70.2×37.6%

How Mankind Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Mankind Pharma against its 20 peers (data as of 18 Nov 2026)
MeasureMANKIND.NSPeer medianRank in peer set
1-month return+16.5%+6.4%3rd highest of 21
6-month return+5.3%+7.6%11th highest of 21
Distance from 52-week high-3.0%-7.6%6th highest of 21
Revenue growth (TTM)+13.3%+14.5%7th lowest of 20
Operating margin20.6%20.1%10th highest of 19
Forward P/E44.4×30.9×5th most expensive of 17
Growth the price implies (Req g, 7 yrs)28.6%12.4%6th most demanding of 15
Growth delivered (Del g)+18.1%+11.9%4th highest of 15
Hurdle (Req g minus delivered)+10.5 pp-11.2 pp6th most demanding of 15
ROIC minus cost of capital+0.5 pp+3.3 pp7th lowest of 19
EV / EBITDA27.3×17.1×5th most expensive of 13
Net debt / EBITDA0.7×0.3×6th most indebted of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Mankind Pharma MANKIND.NSIndia$11.6B+5%+13%21%44.4×28.6%+18.1%
Zhangzhou Pientzehuang Pharmaceutical 600436.SSChina$11.6B-4%-19%19%40.7×24.9%+6.8%
Recordati REC.MIItaly$12.0B+3%+8%30%16.6×1.1%+12.6%
Repligen RGENUnited States$11.0B+55%+14%9%71.0×56.9%+15.0%
Sbp 1177.HKHong Kong$12.2B+5%+15%30%17.5×-5.7%+5.4%
Dr. Reddy's Laboratories DRREDDY.NSIndia$12.5B+5%-4%9%32.0×30.7%+12.1%
Zydus Lifesciences ZYDUSLIFE.NSIndia$12.8B+18%+24%17%30.0×n/an/a
Sichuan Kelun-Biotech Biopharmaceutical 6990.HKHong Kong$13.0B-1%+44%-38%1,176.1×55.3%+33.6%
TG Therapeutics TGTXUnited States$9.99B+66%+69%21%25.2×43.0%+426.7%
Laurus Labs LAURUSLABS.NSIndia$13.4B+73%+23%24%76.4×51.2%+7.3%
Pharmaron Beijing 300759.SZChina$9.90B+52%+18%14%36.8×n/an/a
Spyre Therapeutics SYREUnited States$9.64B+41%n/an/an/an/an/a
Madrigal Pharmaceuticals MDGLUnited States$9.25B-22%+93%-11%81.5×n/an/a
H. Lundbeck A/S HLUN-A.CODenmark$9.16B+69%+9%26%n/a-6.6%+6.6%
Ipsen IPN.PAFrance$14.8B+1%+14%30%10.8×-6.7%+7.2%
Sichuan Biokin Pharmaceutical 688506.SSChina$14.9B-7%+14%-43%n/an/an/a
Yunnan Baiyao 000538.SZChina$15.0B+11%+5%11%18.3×-0.2%+4.7%
PharmaEssentia 6446.TWTaiwan$15.0B+67%+78%40%31.9×23.7%+94.8%
Orion ORNAV.HEFinland$15.7B+41%+34%38%23.6×-6.2%+11.7%
Praxis Precision Medicines PRAXUnited States$8.53B-9%-100%n/an/an/an/a
Jazz Pharmaceuticals Public JAZZUnited States$15.9B+4%+13%25%9.3×-2.8%+12.5%

Questions

Who are Mankind Pharma's main competitors?
Named competitors: Sun Pharmaceutical (SUNPHARMA.NS), Cipla (CIPLA.NS), Zydus Lifesciences (ZYDUSLIFE.NS), Lupin (LUPIN.NS), Torrent Pharmaceuticals (TORNTPHARM.NS). The cockpit's measured peer set (industry) also includes Zhangzhou Pientzehuang Pharmaceutical (600436.SS), Recordati (REC.MI), Repligen (RGEN), Sbp (1177.HK), Dr. Reddy's Laboratories (DRREDDY.NS), Zydus Lifesciences (ZYDUSLIFE.NS).
Is Mankind Pharma expensive compared with its peers?
On forward p/e it trades at 44.4× against a peer median of 30.9×, 5th most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 29% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is +10 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Mankind Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned +5.3% against +7.6% for the median peer; over one year +15.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.